Aeterna Zentaris (AEZS) 0.09 $AEZS
Stock to Watch: AEterna Zentaris Up 19.1% (AEZS)
Comtex SmarTrend(R) - Mon Sep 28, 10:41AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing penny stocks, up 19.1% to $0.10 on 1.9x average daily volume. AEterna Zentaris has traded 50.0 million shares thus far today, vs. average volume of 26.4 million shares per day. The stock has outperformed the Dow (19.1% to the Dow's -1.3%) and outperformed the S&P 500 (19.1% to the S&P's -1.7%) during today's trading.
AEZS: 0.09 (unch)
Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer
CNW Group - Mon Sep 28, 10:00AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced that its lead oncology compound, zoptarelin doxorubicin (formerly AEZSâ??108), met the primary end-point of the investigator-driven and sponsored Phase 2 clinical trial in Castration and taxane Resistant Prostate Cancer (CRPC) and demonstrated good tolerability. The primary endpoint was Clinical Benefit (CB) defined as remaining progression-free by RECIST and Prostate Specific Antigen (PSA) after treatment for 12+ weeks.
AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Technical Coverage on Financial and Healthcare Stocks - CBOE Holdings, Boston Private, AEterna Zentaris, Great Basin Scientific and Gilead Sciences
PR Newswire - Mon Sep 28, 8:03AM CDT
ACI Association has initiated research coverage on the following equities: CBOE Holdings, Inc. (NASDAQ: CBOE), Boston Private Financial Holdings, Inc. (NASDAQ: BPFH), AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD). On Friday, September 25, 2015, Nasdaq ended at 4,686.50 down 1.01%, Dow Jones advanced 0.70%, to finish the day at 16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register for your complimentary reports at the links given below.
GBSN: 0.09 (unch), CBOE: 67.32 (+0.07), GBSNU: 16.22 (-0.28), GILD: 98.28 (+0.01), AEZS: 0.09 (unch), BPFH: 11.54 (-0.14)
Wall St. Analyst Announces Investment Opinion: Weekly Screener - Biotech Stocks Publication
Business Wire - Mon Sep 28, 7:45AM CDT
WallStAnalyst.com's (SEBI Reg. # INH200000147) (www.wallstanalyst.com) 'Weekly Screener' brings investors the fundamental macroeconomic events and market news that shaped equities, commodities and currencies markets last week. It covers global equity indices' performance, commodities' movements and economic releases. Our analysts have also expanded our coverage to include the recent developments in the biotech sector with focus on these companies: Aeterna Zentaris Inc. (NASDAQ: AEZS), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) and Medivation Inc. (NASDAQ:MDVN) in our website's Research Desk category. Visit us for your free biotech companies coverage at:
MDVN: 44.89 (+1.99), ZIOP: 9.80 (+0.60), AEZS: 0.09 (unch), ARNA: 1.98 (+0.17), KERX: 3.20 (+0.01)
Aeterna Zentaris Announces TSX Approval of Series B Warrant Amendment
CNW Group - Fri Sep 25, 3:30PM CDT
All amounts are in US dollars
AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Aeterna Zentaris Announces Dismissal of Class Action Lawsuit
PR Newswire - Thu Sep 24, 8:00AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company" , announced today that the previously disclosed purported class action lawsuit filed against the Company and certain of its current and former officers (the "Defendants" , brought on behalf of shareholders of the Company in the United States District Court for the Southern District of New Jersey, has been dismissed with leave to amend. In dismissing the lawsuit, the Court stated that "taking the complaint as a whole, plaintiffs have failed to state a claim" under the Private Securities Litigation Reform Act of 1995 or Rule 9 of the Federal Rules of Civil Procedure. The plaintiffs have until October 14, 2015, to file an amended complaint or to appeal the Court's decision, if they determine to do so.
AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Market Coverage on the Healthcare Sector -- AEterna Zentaris, Great Basin Scientific, Gilead Sciences, WaferGen Bio-systems and Horizon Pharma
PR Newswire - Tue Sep 22, 7:27AM CDT
ACI Association has initiated research coverage on the following equities: AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD), WaferGen Bio-systems, Inc. (NASDAQ: WGBS), Horizon Pharma plc (NASDAQ: HZNP). On Monday, September 21, 2015, Nasdaq ended at 4,828.95, up 0.04%, DOW advanced 0.77% to finish the day at 16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register for your complimentary reports at the links given below.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28), GILD: 98.28 (+0.01), HZNP: 21.11 (+0.75), AEZS: 0.09 (unch), WGBS: 1.23 (-0.01)
Global Pharma and Biotech M&A Trends 2010-2015: Access to Agreements Entered into by the World's Leading Biopharma Companies
M2 - Tue Sep 22, 6:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hw5rqj/global_pharma_and) has announced the addition of the "Global Pharma and Biotech M&A Trends 2010-2015 (8th Edition)" mergers & acquisitions to their offering. The Global Pharma and Biotech M&A Trends 2010-2015 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all merger and acquisition deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners. Global Pharma and Biotech M&A Trends 2010-2015 report provides the reader with the following key benefits: - In-depth understanding of M&A deal trends since 2010. - Analysis of the structure of M&A agreements with numerous real life case studies. - Comprehensive access to over 2,500 actual M&A deals entered into by the world's biopharma companies, together with contract documents if available. - Detailed access to actual M&A deals entered into by the leading fifty big pharma and big biotech companies. - Insight into the terms included in a M&A agreement, together with real world clause examples. - Full listing of M&A deals by company A-Z and industry sector. - Understand the key deal terms companies have agreed in previous deals. - Undertake due diligence to assess suitability of your proposed deal terms for partner companies. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in M&A dealmaking Chapter 3 - Overview of M&A deal structure Chapter 4 - Leading M&A deals Chapter 5 - Big pharma M&A deals Chapter 6 - Big biotech M&A deals Chapter 7 - M&A contracts directory Companies Mentioned - 30 of the 100 Companies - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys - Atley Pharmaceuticals - Auriga Laboratories - Aventis - AVEO Pharmaceuticals - Barrier Therapeutics - Bayer - Biogen Idec - BioMarin Pharmaceuticals - BioMerieux For more information visit http://www.researchandmarkets.com/research/hw...pharma_and
BIIB: 290.35 (+3.05), ABT: 41.38 (+0.62), AMGN: 142.47 (+2.24), AGN: 288.00 (+5.65), ACAD: 35.12 (+1.92), ACHN: 7.20 (+0.46), AVEO: 1.24 (+0.06), AEZS: 0.09 (unch), ANAC: 128.12 (+7.65), XLRN: 24.67 (+0.46)
Aeterna Zentaris Announces Amendment to Series B Warrants
CNW Group - Mon Sep 21, 8:00AM CDT
All amounts are in US dollars
AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Hot Stock: AEterna Zentaris, Shares Gain 143.8% (AEZS)
Comtex SmarTrend(R) - Fri Sep 18, 11:43AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing penny stocks, up 143.8% to $0.12 on 5.1x average daily volume. Thus far today, AEterna Zentaris has traded 71.2 million shares, vs. average volume of 13.9 million shares per day. The stock has outperformed the Dow (140.0% to the Dow's -1.3%) and outperformed the S&P 500 (140.0% to the S&P's -1.1%) during today's trading.
AEZS: 0.09 (unch)
Biotechnology Equities under the Scanner -- Gilead Sciences, Aeterna Zentaris, RXi Pharma, BioCryst Pharma, and Kite Pharma
PR Newswire - Fri Sep 18, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), Aeterna Zentaris Inc. (NASDAQ: AEZS), RXi Pharmaceuticals Corporation (NASDAQ: RXII), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Kite Pharma Inc. (NASDAQ: KITE). Free research report on Gilead Sciences can be accessed at https://www.erionline.net/reports?keyword=GILD On Thursday, September 17, 2015, the NASDAQ Composite ended at 4,893.95, up 0.10%, the Dow Jones Industrial Average edged 0.39% lower, to finish the day at 16,674.74, and the S&P 500 closed at 1,990.20, down 0.26%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
BCRX: 12.44 (+0.83), RXII: 0.42 (+0.03), KITE: 61.97 (+4.98), GILD: 98.28 (+0.01), AEZS: 0.09 (unch)
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
CNW Group - Thu Sep 03, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chief Financial Officer, Dennis Turpin, will be presenting a corporate overview at the Rodman & Renshaw 17(th) Annual Global Investment Conference on Wednesday, September 9, 2015, at 10:25 am (Eastern), in the Library Room (2(nd) floor) of the St. Regis Hotel in New York City.
AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Hot Stock: AEterna Zentaris, Shares Drop 8.1% (AEZS)
Comtex SmarTrend(R) - Mon Aug 17, 11:42AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's worst performing penny stocks, down 8.1% to $0.13 on 1.1x average daily volume. AEterna Zentaris has traded 5.9 million shares thus far today, vs. average volume of 5.6 million shares per day. The stock has underperformed the Dow (-8.1% to the Dow's 0.2%) and underperformed the S&P 500 (-8.1% to the S&P's 0.3%) during today's trading.
AEZS: 0.09 (unch)
Aeterna Zentaris reports 2Q loss
Automated Insights - Thu Aug 13, 3:54PM CDT
QUEBEC CITY (AP) _ Aeterna Zentaris Inc. (AEZS) on Thursday reported a loss of $15.1 million in its second quarter.
AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Aeterna Zentaris Reports Second Quarter Financial and Operating Results
CNW Group - Thu Aug 13, 3:15PM CDT
Strong fundamentals; pace of transformation accelerates; dilution negatively impacts stock price
AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Stock to Watch: AEterna Zentaris Up 19.1% (AEZS)
Comtex SmarTrend(R) - Mon Sep 28, 10:41AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing penny stocks, up 19.1% to $0.10 on 1.9x average daily volume. AEterna Zentaris has traded 50.0 million shares thus far today, vs. average volume of 26.4 million shares per day. The stock has outperformed the Dow (19.1% to the Dow's -1.3%) and outperformed the S&P 500 (19.1% to the S&P's -1.7%) during today's trading.
AEZS: 0.09 (unch)
Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer
CNW Group - Mon Sep 28, 10:00AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced that its lead oncology compound, zoptarelin doxorubicin (formerly AEZSâ??108), met the primary end-point of the investigator-driven and sponsored Phase 2 clinical trial in Castration and taxane Resistant Prostate Cancer (CRPC) and demonstrated good tolerability. The primary endpoint was Clinical Benefit (CB) defined as remaining progression-free by RECIST and Prostate Specific Antigen (PSA) after treatment for 12+ weeks. AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Technical Coverage on Financial and Healthcare Stocks - CBOE Holdings, Boston Private, AEterna Zentaris, Great Basin Scientific and Gilead Sciences
PR Newswire - Mon Sep 28, 8:03AM CDT
ACI Association has initiated research coverage on the following equities: CBOE Holdings, Inc. (NASDAQ: CBOE), Boston Private Financial Holdings, Inc. (NASDAQ: BPFH), AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD). On Friday, September 25, 2015, Nasdaq ended at 4,686.50 down 1.01%, Dow Jones advanced 0.70%, to finish the day at 16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register for your complimentary reports at the links given below.
GBSN: 0.09 (unch), CBOE: 67.32 (+0.07), GBSNU: 16.22 (-0.28), GILD: 98.28 (+0.01), AEZS: 0.09 (unch), BPFH: 11.54 (-0.14)
Wall St. Analyst Announces Investment Opinion: Weekly Screener - Biotech Stocks Publication
Business Wire - Mon Sep 28, 7:45AM CDT
WallStAnalyst.com's (SEBI Reg. # INH200000147) (www.wallstanalyst.com) 'Weekly Screener' brings investors the fundamental macroeconomic events and market news that shaped equities, commodities and currencies markets last week. It covers global equity indices' performance, commodities' movements and economic releases. Our analysts have also expanded our coverage to include the recent developments in the biotech sector with focus on these companies: Aeterna Zentaris Inc. (NASDAQ: AEZS), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) and Medivation Inc. (NASDAQ:MDVN) in our website's Research Desk category. Visit us for your free biotech companies coverage at:
MDVN: 44.89 (+1.99), ZIOP: 9.80 (+0.60), AEZS: 0.09 (unch), ARNA: 1.98 (+0.17), KERX: 3.20 (+0.01)
Aeterna Zentaris Announces TSX Approval of Series B Warrant Amendment
CNW Group - Fri Sep 25, 3:30PM CDT
All amounts are in US dollars
AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Aeterna Zentaris Announces Dismissal of Class Action Lawsuit
PR Newswire - Thu Sep 24, 8:00AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"
, announced today that the previously disclosed purported class action lawsuit filed against the Company and certain of its current and former officers (the "Defendants" , brought on behalf of shareholders of the Company in the United States District Court for the Southern District of New Jersey, has been dismissed with leave to amend. In dismissing the lawsuit, the Court stated that "taking the complaint as a whole, plaintiffs have failed to state a claim" under the Private Securities Litigation Reform Act of 1995 or Rule 9 of the Federal Rules of Civil Procedure. The plaintiffs have until October 14, 2015, to file an amended complaint or to appeal the Court's decision, if they determine to do so. AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Market Coverage on the Healthcare Sector -- AEterna Zentaris, Great Basin Scientific, Gilead Sciences, WaferGen Bio-systems and Horizon Pharma
PR Newswire - Tue Sep 22, 7:27AM CDT
ACI Association has initiated research coverage on the following equities: AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD), WaferGen Bio-systems, Inc. (NASDAQ: WGBS), Horizon Pharma plc (NASDAQ: HZNP). On Monday, September 21, 2015, Nasdaq ended at 4,828.95, up 0.04%, DOW advanced 0.77% to finish the day at 16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register for your complimentary reports at the links given below.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28), GILD: 98.28 (+0.01), HZNP: 21.11 (+0.75), AEZS: 0.09 (unch), WGBS: 1.23 (-0.01)
Global Pharma and Biotech M&A Trends 2010-2015: Access to Agreements Entered into by the World's Leading Biopharma Companies
M2 - Tue Sep 22, 6:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hw5rqj/global_pharma_and) has announced the addition of the "Global Pharma and Biotech M&A Trends 2010-2015 (8th Edition)" mergers & acquisitions to their offering. The Global Pharma and Biotech M&A Trends 2010-2015 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all merger and acquisition deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners. Global Pharma and Biotech M&A Trends 2010-2015 report provides the reader with the following key benefits: - In-depth understanding of M&A deal trends since 2010. - Analysis of the structure of M&A agreements with numerous real life case studies. - Comprehensive access to over 2,500 actual M&A deals entered into by the world's biopharma companies, together with contract documents if available. - Detailed access to actual M&A deals entered into by the leading fifty big pharma and big biotech companies. - Insight into the terms included in a M&A agreement, together with real world clause examples. - Full listing of M&A deals by company A-Z and industry sector. - Understand the key deal terms companies have agreed in previous deals. - Undertake due diligence to assess suitability of your proposed deal terms for partner companies. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in M&A dealmaking Chapter 3 - Overview of M&A deal structure Chapter 4 - Leading M&A deals Chapter 5 - Big pharma M&A deals Chapter 6 - Big biotech M&A deals Chapter 7 - M&A contracts directory Companies Mentioned - 30 of the 100 Companies - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys - Atley Pharmaceuticals - Auriga Laboratories - Aventis - AVEO Pharmaceuticals - Barrier Therapeutics - Bayer - Biogen Idec - BioMarin Pharmaceuticals - BioMerieux For more information visit http://www.researchandmarkets.com/research/hw...pharma_and
BIIB: 290.35 (+3.05), ABT: 41.38 (+0.62), AMGN: 142.47 (+2.24), AGN: 288.00 (+5.65), ACAD: 35.12 (+1.92), ACHN: 7.20 (+0.46), AVEO: 1.24 (+0.06), AEZS: 0.09 (unch), ANAC: 128.12 (+7.65), XLRN: 24.67 (+0.46)
Aeterna Zentaris Announces Amendment to Series B Warrants
CNW Group - Mon Sep 21, 8:00AM CDT
All amounts are in US dollars
AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Hot Stock: AEterna Zentaris, Shares Gain 143.8% (AEZS)
Comtex SmarTrend(R) - Fri Sep 18, 11:43AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing penny stocks, up 143.8% to $0.12 on 5.1x average daily volume. Thus far today, AEterna Zentaris has traded 71.2 million shares, vs. average volume of 13.9 million shares per day. The stock has outperformed the Dow (140.0% to the Dow's -1.3%) and outperformed the S&P 500 (140.0% to the S&P's -1.1%) during today's trading.
AEZS: 0.09 (unch)
Biotechnology Equities under the Scanner -- Gilead Sciences, Aeterna Zentaris, RXi Pharma, BioCryst Pharma, and Kite Pharma
PR Newswire - Fri Sep 18, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), Aeterna Zentaris Inc. (NASDAQ: AEZS), RXi Pharmaceuticals Corporation (NASDAQ: RXII), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Kite Pharma Inc. (NASDAQ: KITE). Free research report on Gilead Sciences can be accessed at https://www.erionline.net/reports?keyword=GILD On Thursday, September 17, 2015, the NASDAQ Composite ended at 4,893.95, up 0.10%, the Dow Jones Industrial Average edged 0.39% lower, to finish the day at 16,674.74, and the S&P 500 closed at 1,990.20, down 0.26%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
BCRX: 12.44 (+0.83), RXII: 0.42 (+0.03), KITE: 61.97 (+4.98), GILD: 98.28 (+0.01), AEZS: 0.09 (unch)
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
CNW Group - Thu Sep 03, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced that the Company's Chief Financial Officer, Dennis Turpin, will be presenting a corporate overview at the Rodman & Renshaw 17(th) Annual Global Investment Conference on Wednesday, September 9, 2015, at 10:25 am (Eastern), in the Library Room (2(nd) floor) of the St. Regis Hotel in New York City. AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Hot Stock: AEterna Zentaris, Shares Drop 8.1% (AEZS)
Comtex SmarTrend(R) - Mon Aug 17, 11:42AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's worst performing penny stocks, down 8.1% to $0.13 on 1.1x average daily volume. AEterna Zentaris has traded 5.9 million shares thus far today, vs. average volume of 5.6 million shares per day. The stock has underperformed the Dow (-8.1% to the Dow's 0.2%) and underperformed the S&P 500 (-8.1% to the S&P's 0.3%) during today's trading.
AEZS: 0.09 (unch)
Aeterna Zentaris reports 2Q loss
Automated Insights - Thu Aug 13, 3:54PM CDT
QUEBEC CITY (AP) _ Aeterna Zentaris Inc. (AEZS) on Thursday reported a loss of $15.1 million in its second quarter.
AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
Aeterna Zentaris Reports Second Quarter Financial and Operating Results
CNW Group - Thu Aug 13, 3:15PM CDT
Strong fundamentals; pace of transformation accelerates; dilution negatively impacts stock price
AEZ.TO: 0.12 (+0.01), AEZS: 0.09 (unch)
